Similar adverse events from two disparate agents implicate lipid inflammatory mediators for a role in anxiety states.
研究デザイン
- 研究タイプ
- Case report
- サンプルサイズ
- 1
- 対象集団
- Single case report of a 54-year-old male experiencing maintenance insomnia, generalized anxiety, and panic symptoms associated with EPA-enriched fish oil supplement, and subsequently with montelukast (leukotriene receptor antagonist).
- 介入
- Similar adverse events from two disparate agents implicate lipid inflammatory mediators for a role in anxiety states. Fish oil supplement enriched in EPA (dose not specified); also montelukast (leukotriene receptor ant
- 比較対照
- No treatment
- 主要アウトカム
- Anxiety, panic symptoms, and maintenance insomnia associated with EPA-enriched fish oil and montelukast
- 効果の方向
- Negative
- バイアスリスク
- High
抄録
We recently reported a case in which a 54-year-old male experienced maintenance insomnia, generalized anxiety and panic symptoms associated with consumption of a fish oil supplement enriched in eicosapentaenoic acid (EPA). We report here that the same patient has experienced identical but more severe symptoms in response to the use of the leukotriene receptor antagonist montelukast, in accordance with other cases reported to the Food and Drug Administration. Since omega-3 fatty acids like EPA are precursors for the biosynthesis of eicosanoids including leukotrienes, a common factor to these psychiatric adverse events may be perturbations in this highly complex system of lipid inflammatory mediators.
要約
It is reported that the same patient has experienced identical but more severe symptoms in response to the use of the leukotriene receptor antagonist montelukast, in accordance with other cases reported to the Food and Drug Administration.